| Followers | 74 |
| Posts | 1809 |
| Boards Moderated | 0 |
| Alias Born | 04/02/2010 |
Wednesday, June 27, 2012 11:50:21 AM
7 http://www.scribd.com/doc/98433773
Filed & Entered: 06/21/2012
Affidavit of Service
Docket Text: Affidavit of Service of the Notice of Commencement of Chapter 11 Cases and Hearing on First-Day Motions (related document(s)6) filed by Erica R. Feynman on behalf of Atrinsic, Inc.. (Feynman, Erica)
8 http://www.scribd.com/doc/98434158
http://www.scribd.com/doc/98434160
http://www.scribd.com/doc/98434161
http://www.scribd.com/doc/98434164
Filed & Entered: 06/22/2012
Application to Employ
Docket Text: Application to Employ Donlin, Recano & Company, Inc. as Noticing Agent for the Debtor Pursuant to 28 U.S.C. § 156(c), 11 U.S.C. § 105(a), S.D.N.Y. LBR 5075-1 and General Order M-409 filed by Erica R. Feynman on behalf of Atrinsic, Inc.. (Attachments: # (1) Exhibit "A" Engagement Agreement# (2) Exhibit "A" Noticing Agent Affidavit# (3) Exhibit Exhibit "C" - Proposed Order) (Feynman, Erica)
9 http://www.scribd.com/doc/98433777
Filed & Entered: 06/22/2012
Notice of Appearance
Docket Text: Notice of Appearance filed by Adam H. Friedman on behalf of Iroquois Master Fund, Ltd., Hudson Bay Master Fund, Ltd.. (Friedman, Adam)
10 http://www.scribd.com/doc/98433779
Filed & Entered: 06/22/2012
Statement
Docket Text: Statement /Verified Statement Pursuant to Rule 2019 of Federal Rules of Bankruptcy Procedure of Olshan Frome Wolosky LLP filed by Adam H. Friedman on behalf of Hudson Bay Master Fund, Ltd., Iroquois Master Fund, Ltd.. (Friedman, Adam)
"All Truth, In The Long Run, Is Only Common Sense Clarified. ~ Thomas H. Huxley
"Facts Do Not Cease To Exist Because They Are Ignored." ~ Aldous Huxley
Recent PTIX News
- Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 • ACCESS Newswire • 03/17/2026 12:00:00 PM
- Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market • ACCESS Newswire • 03/10/2026 12:00:00 PM
- Results from Phase 1 Multiple-Dose Study of PT00114 • ACCESS Newswire • 12/09/2025 01:46:00 PM
- Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice • ACCESS Newswire • 11/27/2025 08:45:00 AM
- Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study • ACCESS Newswire • 11/13/2025 01:22:00 PM
- Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates • GlobeNewswire Inc. • 07/30/2025 12:30:00 PM
- Nasdaq Top 5 Premarket Losers • IH Market News • 05/20/2025 12:47:37 PM
- Protagenic Therapeutics Soars 190% on Merger to Launch Neuroactive Biopharma Firm • IH Market News • 05/19/2025 02:28:09 PM
- Nasdaq Top 5 Premarket Gainers • IH Market News • 05/19/2025 01:07:08 PM
